Pfizer-BioNTech and AstraZeneca vaccines offer high protection against severe COVID-19, 6 months after second doses, finds study of over 7 million adults

Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.

Kids and the COVID-19 Vaccine: Eleven Key Questions Answered

With the vaccine for children ages 6 months and older approved, the experts at Children’s Hospital Los Angeles provide guidance for families. The Centers for Disease Control and Prevention (CDC) recommends that everyone approved to receive a COVID-19 vaccine get one—including children ages 6 months and older.

New Oral Antiviral Drug Reduces Death in Early COVID-19

Researchers note that health care providers are now able to add to their armamentarium against COVID-19 their prescription of this new antiviral drug for high-risk, newly-infected patients as soon as possible following diagnosis or within five days of the onset of symptoms.

FDA authorization of COVID-19 vaccine for kids 5 to 11: IU experts available to comment

Following a daylong meeting Oct. 26, the FDA authorized Pfizer’s COVID-19 vaccine for use in children ages 5 to 11. This was the first in a series of meetings to make this vaccine available to younger children. Next, the Advisory…

10 questions you want answered on COVID-19

Should children under the age of 12 be vaccinated against COVID-19? Is it possible to achieve herd immunity? Will an 80 per cent vaccination rate keep us safe? In this video, UniSA epidemiologist Professor Adrian Esterman answers these questions and a lot more. The former World Health Organization consultant shares his expertise – 50 years’ worth – and argues for a different approach to tackling COVID-19.
https://www.youtube.com/watch?v=MLKC9q9yEto

New study: Nursing home residents, health care workers lose more than 80% of their COVID-19 immunity six months after Pfizer vaccine

A new, multi-institutional study led by Case Western Reserve University—in partnership with Brown University—found that COVID-19 antibodies produced by the Pfizer vaccine decreased sharply in senior nursing home residents and their caregivers six months after receiving their second shots.

Claim that the first COVID-19 vaccine that was approved by the FDA is somehow different than than the “Pfizer vaccine” currently available is misleading

In the podcast and video show “War Room” hosted by Steve Bannon, Dr. Robert Malone claimed that the “mainstream media is lying” and suggested that the vaccine that was approved by the FDA is somehow different than the “Pfizer vaccine” currently available under emergency use authorization.

Yale Cancer Center Perspective Highlights New Advances for NSCLC

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.

Rutgers Pediatric Infectious Disease Expert Available to Discuss Pfizer’s Vaccine Approved by FDA for Children

Pediatric infectious disease expert David Cennimo is available to discuss the Food and Drug Administration approving Pfizer’s COVID-19 vaccine for emergency use on kids ages 12 to 15. “The Pfizer vaccine had a great track record of safety and success since…

6 important things to know about your COVID-19 vaccine card

Everyone who gets vaccinated for COVID-19 in the U.S. receives a vaccine card. Sarah Lynch, clinical assistant professor of pharmacy practice at Binghamton University, State University of New York, offers insight into why vaccine cards are important and why you…

AACI Applauds Approval of COVID-19 Vaccine, Supports Widespread Vaccination Efforts

The Association of American Cancer Institutes (AACI) commends the U.S. Food and Drug Administration (FDA) for its swift action to grant Emergency Use Authorization (EUA) to Pfizer’s COVID-19 vaccine.

NCCN Announces Research Projects Exploring Axitinib in Various Cancers, in Collaboration with Pfizer

National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.

Rutgers Expert Available to Discuss Rich Countries Hoarding Coronavirus Vaccine

Richard Marlink, director of the Rutgers Global Health Institute, is available to discuss the global health impact of coronavirus vaccine hoarding by rich countries and how such measures may derail worldwide efforts in fighting the pandemic. “Hoarding of vaccines by…

UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates

Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.

Pfizer, Moderna news is promising, but billions are unlike to get COVID-19 vaccine for years

In just a week, both Moderna and Pfizer have announced that they have developed effective vaccines against COVID-19 — but how long will it be before everyone has access to them? According to Nicole Hassoun, professor of philosophy at Binghamton…

[email protected] researcher @rmalosh discusses the results of the interim efficacy analysis, shared today by Pfizer and BioNTech, is available to discuss with the media.

Ryan Malosh, assistant research scientist at the University of Michigan School of Public Health, can comment on today’s announcement by Pfizer and BioNTech. His research focuses on vaccine effectiveness, epidemiology and transmission of respiratory viruses, and social determinants of acute…